Verona Pharma Share Discussion Threads

[meijiman] 01/10/2015 12:05

doesn't seem to be helping the sp!

[the oxford whale] 01/10/2015 11:22

New hardman research note out. On their website.

[thebossman] 29/9/2015 14:01

This morning RNs was life changing if we are nearly at a product stage and the share price is still rubbish when you consider how much money vrp have invested..

[corbine] 29/9/2015 11:15

depending how you look at it? weve come a long way since january of this year when we slumped around 1.15pence? so much has happened since 700 got dunked and new team, formulations etc etc.
i want to see more publicity not just peer review, lancet , but much more publicity-after all 554 to date is proving significant in its field, but wheres the pr?
agree with neds etc need to purchase some stock now to show how much they like latest results.
vas/timbo etc, what about the muco aspect? surely theyve held a lot if info from trial back, maybe thats coming with peer review?
the rns could have told us more than the fev1? etc
wish they would talk to investors on phone even discussing 554 generally?
corbs :-)

[thebossman] 29/9/2015 10:52

Vas if I could have afforded to buy £20k Worth before the rise this morning I would have sold too,as always its the people who have money to invest that will profit the most.

[vasilis] 29/9/2015 10:45

thebossman/meijiman

No doubt short term traders would have already taken positions in anticipation of positive results and are now doing what they usually do when the news breaks - sell. That's the nature of the business and nothing wrong with that.

Near term it would be good to see the new Non-execs now put their hands in their pockets and buy shares - plus I expect updated broker notes may also help the share price - and one or two larger holders may increase their positions. In addition, see again the last Hardman report which valued RPL554 getting through this latest trial at a median value of 19p per share (hardman research link 8 September). Good news over the next six months in respect of CF and asthma can only increase this valuation.

This is only the beginning for the new formulation of RPL554, so plenty more to come for the patient investor.

[corbine] 29/9/2015 10:24

id like to see the rest of the info theyve gleaned from the study, not only peered, but other interesting aspects, re tolerability, competitor comparisons for same stages etc etc the breos of the world.
no mention of the muco clearing which they surely have data on? and that will be useful not only to copd, bronchitis patients but the cf patients too.
suppose they are excited with the results as its useful in many ways moving forward not only for 554?.
peer review? any ideas how long? before christmas?
:-) jmo

[meijiman] 29/9/2015 09:42

Thought this would stay above 5p on that update. But its yet another bad news day in the market which can't be helping.

[thebossman] 29/9/2015 09:25

Lets hope the MMs dont shaft us by lowering the share price .????

[vasilis] 29/9/2015 09:24

These headline results look very encouraging ticking all the boxes. They clearly bode well for further positive data in the CF and asthma studies.

There does also seem to be an endpoint at the highest dose and lower doses may be just as effective which might explain why the dose determined in the previously announced asthma study was set at 6mg.

[aimshares] 29/9/2015 08:22

Great results .

[peawacks] 29/9/2015 08:15

("Verona Pharma" or the "Company") Positive headline data from RPL554 clinical study in COPD patients New suspension formulation is well tolerated; results signal marked improvement in lung function RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016

Very nice too.

[gersemi] 29/9/2015 08:13

Looking very good here

[timbo003] 29/9/2015 07:20

The results reported today are a tad early, they were due early Q4 (according to the time line in the header).

They results really couldn't be much better than this.

* Very large improvement in FEV
* Results support a twice daily dosing regime.
* Placebo like side effect profile.

I predict an up day today.

[gersemi] 29/9/2015 07:18

Interesting indeed

[just_banter] 29/9/2015 07:17

RNS - positive trial results

[timbo003] 25/9/2015 13:26

This caught my eye today:



I recall a number of years ago seeing suggestions that replacing hydrogen with Deuterium could alter enzyme kinetics (and rate of elimination) for certain drugs, but I didn't realise anyone was actually doing it (in humans!)

For the sake of CF suffers the world over I hope Concert are successful and I'll be following this story with interest, however, I suspect that the concept of switching hydrogen for Deuterium is more applicable to drugs which act systemically, rather than those which act topically (i.e. most, if not all drugs given via the inhalation route for respiratory diseases).

[shakin not stirred] 25/9/2015 11:57

jeddi
News soon will give us a clearer indication to whether or not Verona will be here for the long term. My observation and research suggests that they will be going it alone. So I disagree with bang bangs assumption. But all dyor and best of luck.

[jeddicat] 25/9/2015 09:59

Bangbang1 - Why?

Regards

[bangbang1] 23/9/2015 10:33

We have a lot of non exec Directors. That itself seems Verona pharma won't be here for the long term.

[ewads] 14/9/2015 09:30

Amazing: when WNews appears ramping the share price drops!

[just_banter] 14/9/2015 07:43

Let hope for a great week.

[shakin not stirred] 13/9/2015 18:06

Banter - no newbie. Just do not hold numerous AKA's like yourself IMHO.